Go or no go? Oncology dominates upcoming decisions
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
AACR 2020 – Thrive steals a march
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.
AACR 2020 – Gracell validates a novel Car-T target
The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
AACR 2020 – Verastem reveals the logic behind its Kras deal
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
The crucial data readouts coming soon for small biotechs
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Bayer’s big kidney disease readout approaches
Bayer has invested heavily in finerenone in kidney disease, but the window of opportunity has narrowed. Data will soon show whether it has shut completely.
Will Novo’s big thinking in obesity pay off?
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
ACC 2020 – Merck and Bayer face a fight with new heart failure pill
Merck & Co and Bayer’s vericiguat was deemed another “win” for heart failure at a medical conference this weekend. But widespread use looks unlikely.
